Clinical Trials

    Showing 1 - 4 of 4 Zeenat Safdar

    Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied thr... Read more >

    Pulmonary Hypertension Association Registry (PHAR)

    Status: Open Not Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Royanne Holy

    Phone: 713.363.7536

    The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participa... Read more >

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Ana Lucia Varon Ocampo

    Phone: 713.363.8024

    Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific background t... Read more >

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Ana Lucia Varon Ocampo

    Phone: 713.363.8024

    Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. Subjec... Read more >